Should You Buy Cellectis SA (CLLS) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
4.060
1 Day change
-4.02%
52 Week Range
5.480
Analysis Updated At
2026/01/28
Not a good buy right now for a beginner long-term investor who is impatient. The stock is in a short-term downtrend with weakening momentum and is trading near support (~$3.99). Options flow is skewed bearish on volume with extremely high implied volatility, suggesting elevated downside risk near-term. While Wall Street has a bullish initiation with a large upside target, there’s no fresh news catalyst this week and no proprietary buy signals today—so the risk/reward is not attractive for an immediate entry.
Technical Analysis
Price/Trend: CLLS is down -3.78% to $4.07 in the regular session, sitting below the pivot (4.204) and near first support (S1=3.988), with next support at S2=3.855. Momentum: MACD histogram is negative (-0.02) and expanding lower, signaling weakening momentum. RSI(6)=39.44 is neutral-to-weak (not oversold), implying room for further downside before a technical rebound is statistically favored. Moving Averages: Converging moving averages suggest no clear uptrend and a “compression” phase that often precedes a larger move—currently biased down given MACD/price action. Key levels to watch: Support 3.99 then 3.86; resistance 4.42 then 4.55.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Sentiment read-through: Open interest put/call (0.12) is call-heavy positioning overall, but today’s option volume put/call (4.2) is strongly put-skewed, indicating near-term bearish trading/hedging despite call-heavy outstanding positions. Volatility: 30D IV is extremely high (~267.6%) vs historical volatility (~90.6%), and today’s volume is far above average (325% of avg), consistent with heightened uncertainty and “event-like” pricing even though no news is listed this week. Net: options market is signaling elevated risk and near-term caution.
Technical Summary
Sell
8
Buy
3
Positive Catalysts
- Wall Street catalyst: Clear Street initiated coverage (2025-12-22) with a Buy and $9 PT, citing strong efficacy data and encouraging early signals in Cellectis’ allogeneic CAR-T programs.
- Strategic upside: If clinical progress continues, the company could be positioned among earlier allogeneic CAR-T entrants in hematological cancers.
- Pre-market is slightly positive (+0.47%), suggesting some dip-buying interest after the regular-session drop.
Neutral/Negative Catalysts
- No fresh news in the past week, so there’s no immediate event-driven tailwind to reverse the current downtrend.
- Technical weakness: price below pivot with a bearish MACD expansion; RSI not yet oversold.
- Options are pricing extreme uncertainty (very high IV) and today’s flow is put-dominant—often a near-term bearish tell.
- Trading trends: Hedge funds neutral; insiders neutral (no supportive accumulation signals from either group).
Financial Performance
Financial data for the latest quarter was not provided (data error: “list index out of range”), so quarter/season growth trends (e.g., revenue, cash burn, runway) cannot be assessed here. Without those numbers, it’s harder to justify an immediate long-term buy for a beginner in a high-volatility biotech.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: Limited coverage data provided; the notable change is a bullish initiation from Clear Street on 2025-12-22 (Buy, $9 PT). Wall Street pros: meaningful upside implied from ~$4 to $9 and confidence in early efficacy signals. Wall Street cons: this is still a clinical-stage, high-volatility setup where timing matters; current market/technical signals do not confirm a clean entry right now.
Politician/influential trading: No recent Congress trading data available in the last 90 days.
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 7 USD with a low forecast of 4 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast CLLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLLS is 7 USD with a low forecast of 4 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 4.230
Low
4
Averages
7
High
9
Current: 4.230
Low
4
Averages
7
High
9
Clear Street
Bill Maughan
initiated
$9
AI Analysis
2025-12-22
Reason
Clear Street
Bill Maughan
Price Target
$9
AI Analysis
2025-12-22
initiated
Reason
Clear Street analyst Bill Maughan initiated coverage of Cellectis with a Buy rating and $9 price target. Cellectis has produced "strong" efficacy data from its initial program, lasme-cel in acute lymphoblastic leukemia, and "an encouraging initial efficacy signal" from eti-cel in non-hodgkin's lymphoma, which the firm believes positions Cellectis well to be among the first companies to bring an allogenic CAR-T product for the treatment of hematological cancers to market.
Wells Fargo
Nick Abbott
Equal Weight
maintain
$3 -> $4
2025-10-20
Reason
Wells Fargo
Nick Abbott
Price Target
$3 -> $4
2025-10-20
maintain
Equal Weight
Reason
Wells Fargo analyst Nick Abbott raised the firm's price target on Cellectis to $4 from $3 and keeps an Equal Weight rating on the shares. The firm says new data from DL3 of ALL study are promising, with high CR/CRi & MRD-ve rates in patients with few options. Clarity on regulatory path is also positive, Wells adds. Pivotal Phase 2 execution is now key, with first data Q4 2026 and BLA filing in the second half of 2028, along with clarity on market size/opportunity.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLLS
